Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)

Adrenocortical Carcinoma Clinical Trial

— PESETA  

Official title:

Prospective, Phase II Study to Evaluate the Efficacy of Addition of Progesterone to Standard Chemotherapy According to Etoposide-Doxorubicin-Cisplatin Scheme Plus Mitotane (EDP-M) in Patients With Advanced Adrenocortical Carcinoma (ACC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05913427
• Other study ID #: ASSTBS-FARONCO- PESETA-20
• Status: Recruiting
• Phase: Phase 2
• Start date: June 8, 2022
• Est. completion date: June 8, 2027

Study information

• Verified date: January 2023
• Source: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
• Contact: Aldo Roccaro
• Phone: +390303996851
• Email: coordinamento.ricerca[@]asst-spedalicivili.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective randomized, double blind, placebo controlled phase II study planned in patients with advanced ACC. The study will be conducted at ASST Spedali Civili Hospital and University of Brescia in Brescia.

Description:

As no effective second-line therapies are available for patients with disease progression to EDPM, including modern molecular target therapies and immunotherapy, it is reasonable to expect that no newer drugs or combination regimens will be able to replace EDPM in the next 5 years. Since EDP-M is destined to remain the standard first line therapy, research strategies aimed to improve the efficacy of this regimen are of relevance. In this study, investigators will address the hypotheses that progesterone has a synergistic and/or additive effect to EDP-M in inducing cytotoxicity in ACC cells in vitro and the antineoplastic activity of EDP-M in locally advanced/metastatic ACC patients could be improved by the addition of megestrol acetate.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: June 8, 2027
• Est. primary completion date: June 8, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed diagnosis of ACC
• Locally advanced or metastatic disease not amenable to radical surgery resection
• ECOG performance status 0-2
• Effective contraception
• Life expectancy > 3 months
• Age > 18 years
• Adequate bone marrow reserve (neutrophils >1,000/mm3 and/or platelets >80,000/mm3) and organ function (including renal, liver and cardiac function)
• Be able to comply with the protocol procedures and provide written informed consent.

Exclusion Criteria:

• History of recent or active prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, breast ductal carcinoma in situ, or other treated malignancies where there has been no evidence of disease for at least 2 years
• Renal insufficiency (estimated glomerular filtration rate [GFR]<50 mL/min/1.73 m2) or significant liver insufficiency (serum bilirubin>2 times the upper normal range and/or serum alanine aminotransferase [ALT] or aspartate aminotransferase [AST]>3 times the upper normal range). GFRs will be calculated according to the validated formula (MDRD)
• Pregnancy or breast feeding
• Congestive heart failure (ejection fraction<45%)
• Preexisting grade 2 peripheral neuropathy
• Previous or current treatment with mitotane or other antineoplastic drugs for ACC
• Previous radiotherapy for ACC
• Any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration or that, in the judgment of the investigator, would make the patient inappropriate for entry into this study.

Related Conditions & MeSH terms

• Adrenocortical Carcinoma
• Carcinoma

Intervention

Drug:
• Etoposide, doxorubicin, cisplatin and Mitotane plus Megestrol Acetate 160 MG
EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Megestrol acetate will be prepared and packaged by the authorized external contract development and manufacturing organization (CDMO) Doppel Farmaceutici s.r.l. (Cortemaggiore, PC), that, according to the GMP and applicable law (FU XII ed) will also prepare the related placebo, in accordance with GMP (annex 13) and applicable law (FU XII ed.).
• Etoposide, doxorubicin, cisplatin and Mitotane plus Placebo
EDP will be administered at the following doses: doxorubicin 40 mg/m2 on day 1, etoposide 100 mg/m2 days 2-4, cisplatin 40 mg/m2 days 3-4, every 28 days. Placebo 160 mg tablets will be developed by the CDMO to have the same appearance and taste as the tablet containing the active drug.

Locations

Country	Name	City	State
Italy	Alfredo Berruti	Brescia

Sponsors (1)

Lead Sponsor	Collaborator
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Country where clinical trial is conducted

Italy, 

References & Publications (5)

Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, de Krijger R, Porpiglia F, Terzolo M, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Adrenocortical carcinomas and malignant phaeochromocy — View Citation

Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B, Sorbye H, Torpy DJ, Stepan V, Schteingart DE, Arlt W, Kroiss M, Leboulleux S, Sperone P, Sundin A, Hermsen I, Hahner S, Willenberg HS, Tabar — View Citation

Fiorentini C, Fragni M, Perego P, Vezzoli S, Bonini SA, Tortoreto M, Galli D, Claps M, Tiberio GA, Terzolo M, Missale C, Memo M, Procopio G, Zaffaroni N, Berruti A, Sigala S. Antisecretive and Antitumor Activity of Abiraterone Acetate in Human Adrenocorti — View Citation

Fragni M, Fiorentini C, Rossini E, Fisogni S, Vezzoli S, Bonini SA, Dalmiglio C, Grisanti S, Tiberio GAM, Claps M, Cosentini D, Salvi V, Bosisio D, Terzolo M, Missale C, Facchetti F, Memo M, Berruti A, Sigala S. In vitro antitumor activity of progesterone — View Citation

Rossini E, Tamburello M, Abate A, Beretta S, Fragni M, Cominelli M, Cosentini D, Hantel C, Bono F, Grisanti S, Poliani PL, Tiberio GAM, Memo M, Sigala S, Berruti A. Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Mod — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of the activity of the combination regimen (EDP-M plus progesterone (EDP-MP) versus EDP-M plus placebo) in advanced/ metastatic patients with ACC.	Comparison of proportion of patients attaining an Objective Response (Objective Response Rate, ORR), evaluated by RECIST criteria between the 2 treatment arms.	18 months
Secondary	Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;	Changes in serum cortisol from baseline in the two treatment arms;	18 months
Secondary	Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;	Changes in serum UFC from baseline in the two treatment arms;	18 months
Secondary	Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;	Changes in serum salivary cortisol from baseline in the two treatment arms;	18 months
Secondary	Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;	Changes in ACTH from baseline in the two treatment arms;	18 months
Secondary	Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;	Changes in serum 11-deoxycortisol from baseline in the two treatment arms;	18 months
Secondary	Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;	Changes in serum aldosterone from baseline in the two treatment arms;	18 months
Secondary	Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;	Changes in serum PRA from baseline in the two treatment arms;	18 months
Secondary	Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;	Changes in serum androstenedione from baseline in the two treatment arms;	18 months
Secondary	Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;	Changes in serum DHEA-S from baseline in the two treatment arms;	18 months
Secondary	Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;	Changes in serum progesterone from baseline in the two treatment arms;	18 months
Secondary	Evaluation of the impact of the combination of the two treatments on hormone response in patients with secreting ACC;	Changes in serum total testosterone from baseline in the two treatment arms;	18 months